Lenacapavir offers a twice-yearly injectable option for HIV prevention, demonstrating high efficacy in trials, particularly benefiting populations with adherence challenges.

Marinus Pharmaceuticals announced a workforce reduction of approximately 45% following disappointing Phase III trial results for oral ganaxolone in tuberous sclerosis complex.

The ACCC is concerned that Blackstone's acquisition of I'rom Group could substantially lessen competition in the Australian phase 1 clinical trial market.

Sarepta Therapeutics discontinues vesleteplirsen (SRP-5051) development for Duchenne muscular dystrophy due to safety concerns and FDA feedback.

A meta-analysis of phase III trials reveals that prior dengue infection reduces the risk of virologically confirmed dengue in subsequent infections.

Melt Pharmaceuticals has completed dosing in its Phase 3 trial of MELT-300, a non-IV, non-opioid sublingual tablet for procedural sedation during cataract surgery.

A recent study reveals that racial and ethnic diversity in head and neck cancer clinical trials in the U.S. has worsened over the past decade.

Neuralink has gained approval to conduct a clinical trial in Canada, marking its first venture outside the United States, focusing on assessing the safety and functionality of its brain implant.

A recent study published in the American Journal of Human Genetics by PacBio and Radboud University Medical Center highlights the transformative potential of HiFi long-read sequencing technology in diagnosing rare diseases. The study demonstrated a 93% success rate in identifying pathogenic variants, offering a more comprehensive and cost-effective diagnostic approach. This collaboration is paving the way for the integration of HiFi sequencing into clinical practice, with significant advancements in sample processing and operational efficiency.

The University of Alabama at Birmingham (UAB) is conducting several clinical trials aimed at advancing medical research and treatment options. These studies cover a wide range of health issues, including obesity and type 2 diabetes, nearsightedness in children, vision rehabilitation for older adults, schizophrenia in older individuals, urinary leakage, HIV vaccine research, and the effects of new medications on type 2 diabetes and blood pressure. Participants may receive medical care, lifestyle counseling, and compensation for their time and involvement.

A groundbreaking University of Oxford study reveals that prior cytomegalovirus (CMV) infection improves melanoma patients' response to single-drug PD-1 immunotherapy while reducing severe side effects.

A major phase 3 clinical trial (SWOG S1815) is evaluating the potential benefits of adding nab-paclitaxel to the standard gemcitabine-cisplatin regimen for advanced biliary tract cancer patients.

Recent research indicates that over half of women aged 30-35 already experience moderate to severe perimenopause symptoms, yet most wait decades before seeking treatment.

University of Sheffield researchers have developed a new nanoparticle-based immunotherapy that significantly delays resistance to androgen deprivation therapy (ADT) in prostate cancer patients.

A recent study emphasizes the importance of the estimand framework in analyzing patient-reported outcomes (PROs) within single-arm trials, particularly in oncology.

SPIMA Therapeutics emerges from a collaboration between IBMM and IRBM, specializing in peptide chemistry and inflammation pharmacology, respectively, to develop novel immunotherapies.

A Phase 2 study of nipocalimab demonstrated a 54% live birth rate at or after 32 weeks gestational age without the need for intrauterine transfusion (IUT) in high-risk pregnancies.

FIRE1 has completed enrollment in the FUTURE-HF2 study, evaluating its novel system for remote heart failure monitoring.

A Phase I clinical trial evaluated the safety and efficacy of allogeneic natural killer (NK) cell therapy in children with relapsed or refractory neuroblastoma.

The FDA is considering limiting the use of PD-1 inhibitors like Keytruda and Opdivo in gastric adenocarcinoma based on PD-L1 expression levels.